Jun. 12 at 3:04 AM
$PGEN $INO
-Sep 2025 FDA approval priced in, early launch prep, analyst upgrades
$2.75–
$3.25
-Oct 2025 Launch
$3.25–
$3.75
-Nov 2025 Early prescription data, insurance uptake updates
$3.50–
$4.25
-Dec 2025 End-of-year analyst coverage
$4.00–
$5.00
-Jan 2026 Q4 update, early patient access data, JPMorgan Healthcare conf.
$4.50–
$5.75
-Feb 2026 First insurance coverage wins, EU trial updates
$5.00–
$6.50
-Mar 2026 Momentum building, buyout rumors possible
$5.50–
$7.00
-Apr 2026 Early revenue guidance or partnership talk $ 6.00–
$7.50
-May 2026 Q1 2026 earnings – first real revenue numbers
$7.00–
$8.50
-Jun 2026 Uptake trends confirmed, cash position stable
$8.00–
$9.50
-Jul 2026 Analysts raise PTs, progress toward international approval
$9.00–
$10.50
-Aug 2026 1-year post-approval anniversary, 12-month sales forecast raised
$10.00–
$12.00
All this is the base case analysis (20% market share) and happening, while
$INO sits on the sidelines.
